Hypothesis

Chronic exposure to pathogenic exosomes triggers a metabolic surrender program in recipient cells, wherein NAD+ biosynthesis is downregulated and NAD+‑consuming pathways are amplified, leading to the NAD+ decline observed in aging and degenerative disease.

Mechanistic Proposal

Pathological exosomes carry damage‑associated molecular patterns (DAMPs) such as oxidized lipids, misfolded proteins, and nucleic acids that activate pattern‑recognition receptors (TLR2/4, NLRP3) on target cells. This initiates a cascade:

1. Receptor signaling → NF‑κB and MAPK activation → transcriptional up‑regulation of PARP1 and CD38 (major NAD+ consumers).
2. Parallel transcriptional repression of NAMPT, the rate‑limiting enzyme in the NAD+ salvage pathway, via HIF‑1α stabilization and increased microRNA‑29 loading from exosomes.
3. Resulting NAD+ pool contraction reduces sirtuin activity, diminishing deacetylation of PGC‑1α and FOXO factors, thereby compromising mitochondrial biogenesis and stress resistance.
4. Feedback loop: Low NAD+ further impairs PARP‑mediated DNA repair, amplifying genomic instability and sustaining inflammasome activation, which perpetuates exosome release from stressed cells.

Thus NAD+ decline is not an upstream driver of aging but a downstream metabolite‑level readout of persistent exosome‑mediated damage signaling—a cellular "budget cut" reflecting diminished expectation of future repair.

Testable Predictions

• Cells treated with exosomes from AD‑ or PD‑affected brains will show rapid (≤6 h) increase in PARP1 activity and CD38 expression, preceding measurable NAD+ loss.
• Blocking TLR2/4 or NLRP3 signaling (with antibodies or MCC950) will prevent NAD+ depletion despite exosome exposure.
• Overexpressing NAMPT or supplying NMN will restore NAD+ levels and rescue sirtuin‑dependent deacetylation targets even in the presence of pathogenic exosomes.
• In vivo, mice with neuron‑specific knockdown of CD38 will exhibit attenuated NAD+ decline and reduced neurotoxicity when challenged with AD‑derived exosomes.

Experimental Approach

1. In vitro: Primary cortical neurons or iPSC‑derived dopaminergic neurons incubated with exosomes isolated from post‑mortem AD/PD brains (characterized by Western blot for Aβ oligomers or α‑synuclein). Measure PARP1 autophagicylation (ELISA), CD38 mRNA (qPCR), NAMPT protein (Western), and NAD+ levels (enzymatic cycling assay) at 0, 3, 6, 12, 24 h.
2. Pharmacological inhibition: Parallel cultures treated with TLR2/4 antagonist (CU‑CPT22) or NLRP3 inhibitor (MCC950). Assess whether NAD+ loss is blocked.
3. Genetic rescue: Lentiviral NAMPT overexpression or CD38 CRISPR‑KO in neurons prior to exosome challenge; evaluate NAD+ recovery and downstream markers (acetyl‑p53, PGC‑1α acetylation).
4. In vivo validation: Stereotactic hippocampal injection of AD‑derived exosomes into wild‑type and CD38‑flox;Camk2a‑Cre mice. Serial MRI‑based NAD+ proxy (NAD+/NADH ratio via MR spectroscopy) and behavioral assays over 8 weeks.

Potential Pitfalls

• Exosome heterogeneity may confound results; use density‑gradient purification and validate cargo consistency.
• Off‑target effects of PARP/CD38 inhibitors could influence NAD+ independently of exosome signaling; include rescue experiments with exogenous NAD+ precursors.
• Compensatory NAD+ biosynthesis pathways (e.g., Preiss‑Handler) might mask NAMPT repression; measure multiple NAD+ synthetases.

If NAD+ depletion is demonstrably a consequence, rather than a cause, of exosome‑driven damage signaling, therapeutic strategies should prioritize exosome interception or blockade of downstream NAD+‑consuming enzymes before attempting NAD+ supplementation alone.